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The analytical performance of the Dimension(R) XL clinical
chemical system was evaluated. The XL is the latest addition to
the Dimension family of instruments; it is a random access
analyser with a throughput up to 740 tests/hour. Regression
analysis ofmethod comparison studies with Dimension ARyielded
slopes of 0"93 to 1"03 and correlation coeicients > 0"96 for 28
assays. Excellent precision performance was also observed. New
instrumentfeatures of the XL are discussed.
Introduction
The Dimension(R) clinical chemistry system is a general
chemistry analyser introduced in 1985. The first version,
the Dimension 380, with a throughput of 380 tests, was
intended for smaller hospital laboratories. The next
generation, Dimension AR, was introduced with a
throughput of 500 tests/hour. The latest, the Dimension(R)
XL clinical chemistry system, was recently introduced
with a throughput of 740 tests/hour. The XL builds on
continued enhancements in the areas of throughput,
automation and ease of use.
The analytical equivalency with earlier models is re-
ported in this paper and details of new instrument
features are given. The evaluation included precision
studies and split sample correlation of tests.
Materials and methods
Instrumentation
General instrumentation and operation of the Dimension
systems have been described elsewhere [1-5]. New
features on XL include automated reagent loading and
unloading; segmented sample carriers, which allow inter-
mixed barcoded and non-barcoded tubes and sample
cups, along with paediatric sample utilization for more
efficient work flow; automatic urine dilutions; and In-
tegrated Multisensor Technology (IMT) for electrolytes.
Urine dilutions are accomplished through the use of an
on-board (self-contained) dilution wheel, while serum
dilutions are done automatically in a cuvette. The system
operation is controlled by a multi-processor computer
system with an internal hard drive. The software pro-
vides such features as one-button daily maintenance and
* Correspondence to N. V. Neelkantan, Tel: (302) 451-3660; fax: (302)
451-4998.
an enhanced quality-control (QC) program which stores
90 days of quality control on board with choice of
Shewhart chart and Westgard rules. The on-board
diagnostics automatically track cycles run on motors
and parts. Parts are serviced and replaced during pre-
ventive maintenance before they fail. Remote diagnostic
capability speeds troubleshooting via a built-in modem.
The uninterruptable power supply keeps the XL sam-
pling and processing for 10 minutes before beginning an
automatic power-down, in the event of loss of power. All
sample results and data are saved. Similar to the Dimen-
sion AR, the XL has two reagent arms capable of
delivering multiple reagents to reaction cuvettes and also
providing mixing through ultrasonics. Reaction cuvettes
are automatically made on-board and sealed for disposal.
Cuvette temperature is controlled to 37"0 + / 0" C. A
rotating photometric arm provides readings at any given
reaction cuvette. The operating cycle time was reduced
from 12 on the AR to 7"2 on the XL to attain the
photometric throughput of 500 tests/hour.
Integrated Multisensor Technology (IMT)
The IMT system for measurement of electrolytes on the
Dimension AR and XL systems was introduced recently.
These methods are processed with an independent mod-
ule from that of the photometric methods which is
capable of 240 tests/hour, for the overall throughput of
740 tests/hour. A unique feature of the IMT system is a
disposable sensor cartridge which incorporates ion-selec-
tive sensors for Na, K, and C1 on a ceramic substrate. The
cartridge also contains its own reference sensor and an
air/liquid detector. The sensor substrate is based on
hybrid thick film technology consisting of layers of
conductor and dielectric material and printed polymer
sensors. A dual channel elastomeric flow path sits directly
over the sensor substrate and directs the sample over the
individual sensors and a reference fluid over the reference
sensor. The sensor cartridge is inserted into a cartridge
interface on the analyser, establishing electrical and
fluidic connections; insertion and removal of the car-
tridge is similar to that of an audio cassette tape.
Electrolyte results are generated using standard potentio-
metric techniques. The TCO2 measurement system,
based on the classical pH electrode, is adjacent to the
cartridge interface and has been integrated with the IMT
system. The cartridge can be used for up to 400 patient
samples or 48 hours (whichever comes first). When
expired, the cartridge is replaced with a new one. No
electrode maintenance is necessary. Current work is also
in progress to allow separate processing of glucose, BUN
and creatinine (currently photometric methods) via
enzyme sensor technology. This will allow further en-
hancement in throughput to 920 tests/hour.
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Software
The Dimension XL software consists of 30 interacting
tasks. These tasks provide an interface with the user,
maintain reagent inventories, schedule instrument activ-
ities and control the various instrument resources. The
tasks are designed around a layered hierarchy, allowing
for real-time control, sophisticated scheduling and future
expansion.
The user’s primary interaction with the Dimension XL
software is the RUN key. After the RUN key has been
pressed, the system will scan for new samples, query the
host for test requests (or automatically set up a default
panel or pre-entered request), allocate reagent and begin
processing samples. If there are system needs, then the
user will be prompted to address those needs.
Other Dimension XL software features include auto-
matic urine dilution, automatic re-run of tests, program-
mable off-hour hydration, an on-board quality control
package, one-button daily maintenance, remote access
capability, and an on-board reliability-oriented main-
tenance system, which tracks part and motor usage. The
XL contains an internal modem for use in remote
troubleshooting. The modem allows Dade personnel
and Dimension XL customers to exchange information.
Secure access to the XL system is provided by password
protection. With the appropriate software, the remote
system supports a variety of hardware platforms. Cur-
rently, Dade interfaces to Dimension XLs using Macin-
tosh Power PCs which are connected through a Xyplex
server to a bank of 16 28"8 K baud modems. The remote
users are shielded from needing to understand the
operation of the XL’s UNIX operating system through
the use of UNIX shell scripts, the AWK programming
language, and general UNIX user/group/world file
and directory protection schemes. File compression and
decompression are provided for the transfer of large
information files.
Reliability
Both hardware and software were monitored, calculated;
evaluated and improved in a closed-loop-corrective-
action environment from prototype to commercializa-
tion of the product. Early reliability predictions allowed
for an improved selection of more robust components on
critical parts. The key metrics of availability, mean cycles
(tests) between failures (MCBF), failure rate, reliability-
growth-slope and Laplace-Trend tests were periodically
calculated to determine the progress of the instrument
reliability during the product development cycle. Both
the hardware and software failure modes encountered
were analysed and eliminated. Finally, all the redesign
activities were verified via software validation/verifica-
tion and hardware reliability testing of the instrument to
assure the effectiveness of corrective actions.
The instruments were subjected to an additional six
months of post-development internal reliability testing
under routine operating conditions to ensure the effec-
tiveness of the design. Decisions on preventative main-
tenance and instrument service schedules were also made
during this period. These efforts have resulted in the
introduction of a product, which the authors believe, is
optimized for field reliability, availability and customer
satisfaction.
Reagents
Reagents, calibrators and verifiers used in the methods
reported in this paper are available from Dade Chemistry
Systems, Inc., Newark, DE 19702.
Specimens
Serum, plasma, cerebrospinal fluid and urine samples for
the method comparison study were obtained from hospi-
tal patients and normal subjects. The analyte concentra-
tions spanned the assay range of tests studied. Multiqual
control sera were obtained from Ciba Corning Diagnos-
tics Corporation, Oberlin, OH.
Experimental procedures
Methods comparison: The performance of the methods
reported here were compared with that of Dimension
AR. Both models of Dimension used the same reagent
cartridge for each method. Both AR and XL instruments
were calibrated prior to conducting the method compar-
ison study. Patient serum/plasma specimens were ana-
lysed on both AR and XL instruments. The samples were
chosen to represent reference interval and assay range.
The sample population included hemolysed, icteric and
lipaemic samples.
Precision: Within-run and total precision were evaluated
according to NCCLS protocol EP5-T2 by duplicate
analysis of two levels of control product on 20 non-
consecutive analysis days.
Heterogeneous immunoassay: This format is used for the
digoxin assay. The heterogeneous immunoassay format
used for digoxin assay is a modification of Dade Chem-
istry System’s ACMIA (Affinity-Column-Mediated
Immunometric Assay) technology [6]. The sample
containing digoxin was mixed and incubated with the
antibody-13galactosidase conjugate. To this mixture was
added oubain coated chromium dioxide. Oubain is an
analogue of digoxin. Free antibody-enzyme conjugate is
retained by the particles while the bound digoxin-anti-
body-enzyme conjugate complex remains in solution.
Separation was achieved by applying a magnetic field
to this mixture. Chromium dioxide particles were pulled
to the side of the cuvette while the supernatant was
withdrawn and added to a second cuvette containing
the substrate chlorophenol red-13-D-galactopyranoside
(CPRG). The change in absorbance at 577 nM over a
defined time interval, due to the formation of chlorophe-
nol red, is directly proportional to digoxin concentration.
The apparatus and method for reagent separation used in
this assay are described in a patent application [7].
Results and discussion
Assay performance
Dimension XL assay performance of methods was com-
pared with that of Dimension AR; the results are shown
in table 1. The representative assays indicated in table
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Table 1. Split sample correlation (comparison method--Dimension AR).
Analyte Units N Slope y-intercept Sy, % TAE
Total protein g/1 {g/dl} 64 0"971
Albumin g/1 {g/dl} 50 0"997
Total bilirubin lamol/1 {mg/dl} 72 0"999
Iron gmol/1 {lag/dl} 34 0"996
Ammonia gmol/1 41 0"999
Calcium mmol/1 {mg/dl} 33 0"981
CKMB U/1 87 0"996
CK U/ .0
Lipase U/1 40 0"998
LDH U/1 48 1"0
Alkaline phosphatase U/1 48 "0
Amylase U/1 39 0"999
Cholesterol mmol/1 {mg/dl} 49 0"998
Triglycerides mmol/1 {mg/dl} 29 0"998
HDL mmol/1 {mg/dl} 17 1"0
Glucose mmol/1 {mg/dl} 79 1"0
Uric acid gmol/1 {mg/dl} 29 0"995
Creatinine gmol/1 {mg/dl} 105 0"999
BUN mmol/1 {mg/dl} 106 0"994
UCFP mg/1 {mg/dl} 49 0"999
Mg mmol/1 {mg/dl} 112 0"992
Phenobarbital lamol/1 {lag/ml} 36 0"993
DGNAb nmol/1 {ng/ml} 24 0"999
Sodium mmol/1 160 0"996
Potassium mmol/1 163 0’998
Chloride mmol/1 175 0"998
TCO2 mmol/1 41 0"996
O’962
1"0
"03
"04
0"99
0"93
0"99
0"99
1"0
0"98
0’98
0"983
1"01
"07
0"97
0"99
10
10
10
10
0 94
0 939
0-989
0"93
1"01
1"01
0"96
3"4 {0"34} 1"9 {0"19} 2"4
1. {O.lS) 0. {0.0) .57
0.62 {0.036) 4.1 {0.24} 3.02
-0. {-1.1) 1. {6.15} 7.
3"28 0"69 14.30
o.a {0.70} o.05 {o.a) 0-7
-.4 .5 8.67
0.59 4.27 1.86
.6 1.6 5.89
"94 2"48 4.46
-3’56 5"3 7"26
0 ’07 0"64
-0"02 {-0"69} 0"12 {4.54} 0"09
-O.O4 {-3.46} 0.081 {7.14} 3.37
0.0 {0.50) 0.0 {0.66)
0.0 {0.50} 0. {.84} .80
7.7 {0.13} 10.7 {0.18} o.26
s.5 {0.04) 0.6 {0.1) 0.
o.oa {0.07) .0 {.7) s.6
0 15.4 {.54) 6.0
0.00 {o.s) o.05 {0.) .5
0"52 {0.12} 5.95 1.38} 8.8
0.06 {0.05} 0.05 {0.04} 0.19
10.39 1.83 1"52
-0"02 0.05 -0"39
1.19 1.4 1.73
2"42 0.76 0"72
Urinary protein cerebrospinal fluid protein;
b Automated digoxin; TAE total analytical error.
include general chemistries, enzyme assays, homoge-
neous immuno assays using Particle Enhanced Turbidi-
metric Inhibition immunoassay technology (PETINIA),
Enzyme Multiplied Immunoassay technology (EMIT)
and heterogeneous immunoassay. In all cases, the results
on Dimension XL compared well with results on
Dimension AR. The relative accuracy was assessed
using the criteria of Westgard and Hunt [8].
Screening assays in urine for drugs of abuse methods are
also part of the Dimension XL menu. The methods
(amphetamine, barbiturates, cocaine metabolite, metha-
done, opiates, phencyclidines and cannabinoids) are
adaptations of the Roche Abuscreen online methods.
These utilize a particle based turbidimetric immunoassay
technique in an all-liquid ready-to-use format. The
qualitative methods are intended for the screening of
urine samples with results expressed in units normalized
to 1000 at the cut-off level. The absorbance change at the
cut-off calibrator level for each method is normalized
during calibration to provide a reference numerical value
arbitrarily set to 1000. These units are referred to as
’normalized qual units’. Negative results are less than
1000 normalized qual units, and positive results are
greater than or equal to 1000 normalized qual units.
The instrument automatically calculates and prints the
results in normalized qual units, as well as positive or
negative.
Precision
Table 2 summarizes the precision results. The precision
performance is equivalent to that of Dimension AR
(product literature).
The new features on XL add considerable value for the
customer. The segmented sample wheel allows samples to
be processed as they arrive in the laboratory, while the
system is in operation, improving work flow and turn-
around time. The sophisticated scheduling system is
constantly looking at the samples in the system, optimiz-
ing both system throughput and ensuring quick STAT
response. As soon as a STAT sample is introduced into
the system, the scheduler will update and reorganize the
pending tests to ensure prompt initiation of the STAT
tests.
The programmable off-hour hydration automatically
prepares reagents during off or slow shift periods. The
reagent set-up screen allows the user to configure the
number of tests that need to be hydrated for each
method. In addition, the user can program a timer, up
to a week in advance, that once activated will begin
preparing reagents. This timer can be programmed to
automatically activate every week, on selected or all
days.
Remote diagnostics is a new feature on XL. Once
connected to the system, a user can view all system
screens and perform all system operations through a
remote monitor and keyboard. This allows the user to
diagnose instrument problems as well as chemistry pro-
blems. In addition to the screen viewing and keyboard
entry capabilities, the user has the ability to either
locally view or download additional troubleshooting
and system information files. All patient specific data is
automatically removed from files to provide for patient
confidentiality.
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Table 2. Within-run precision (N 20).
Analyte Units Mean
Within-run
SD
Total
SD (%cv)
Total protein g/1 {g/dl}
Total bilirubin gmol/1 {mg/dl}
Uric acid gmol/1 {mg/dl}
CK g/
Iron gmol/1 {gg/dl}
LDH U/1
Glucose mmol/1 {mg/dl}
Cholesterol mmol/1 {mg/dl}
Amylase U/1
Phenobarbital lamol/1 {gg/ml}
Automated digoxin nmol/1 {ng/ml}
ALT U/1
T4 nmol/1 {lag/dl}
Tuptake %
Theophylline
U. Amphetamine
U. Barbiturates
U. Cannabinoids
U. Phencyclidiines
U. Opiates
U. Methadone
U. Cocaine
Chloride
Sodium
Potassium
gmol/1 {gg/ml}
qual. units
qual.units
qual/units
qual.units
qual.umts
qual.units
qual.umts
mmol/1
mmol/1
mmol/1
Low 48"3 {4"83}
High 72"9 7"29}
Low 19"2 1.12}
High 123’6 {7"23}
Low 280"2 {4"71}
High 5329 {90}
Low 7898
High 287"63
Low 13"1 {73’2}
High 342 190" 7}
Low 1089
High 2566
Low 48 {86"9}
High 168 3028}
Low 3.3 {126.1}
High 7"3 {283.8}
Low 73.79
High 464.44
Low 38.3 {8.90}
High 166.2 {38"57}
Low 0"74 {0’58}
High 3"95 {3"08}
Low 40" 19
High 181"33
Low 86-2 {6"70}
High 228"2 {17"7}
Low 37’39
High 42"95
Low 30 {5"4}
High 112"1 {30"2}
500
1500
100
3OO
25
75
12"5
37"5
150
450
150
45O
150
450
Low 94"57
High 119"30
Low 124"38
High 154’80
Low 3"20
High 5"68
0.4 {0.04} (0.8)
0.6 {0.06} (0.8)
0.17 {0.01} (0.88)
1.03 {0"06} (0"83)
9.52 {0.16}(3.4)
17.84 {0.30} (3.3)
.o3 (.6)
7.35 (2.6)
0.18 {1.0}(1.4)
0.5 {1.38}(0.7)
1.95 (1 ’8)
3.4,0 (.3)
0.06 {0.99}(1.2)
0"22 {3.93}(1.3)
0.03 {1.27}(1.0)
0.12 {4.81}(1.6)
0.85 (1.1)
6.48 (1"4)
2.4 {0.56}(6.3)
l.1 {2.57}(6.7)
0.03 {0.0}(3.5)
0.08 0.06} (1.9)
1.47 (3’7)
2.13 (1.2)
4.0 {0.31}(4.6)
8"9 {0.69} (3"9)
0.74 (2"0)
0.54 (1.3)
o.6 {o. }(.)
5.83 {1.05}(3.5)
4.7 (0.5)
3.8 (o.6)
6.5 (0.74)
4.0 (0.37)
3.84 (0"46)
3"23 (0.31)
6.9 (0.79)
18 (1’61)
7.59 (0"92)
21.1 (2’02)
10.31 (1"22)
12.41 (1.09)
9.4 (1.04)
10.6 (1.00)
0.45 (0"5)
0.51 (0.4)
1.41 (1.1)
1.47 (1.0)
0.03 (.o)
0.07 (1.2)
0.70 {0.07}(1.4)
0.70 {0.07}(1.0)
1.20 {0.07}(6.25)
1.88 {0.11} 1"52)
9.52 {0.16} 3.4)
17.84 {0.30} 1.52)
3.80 (4.8)
14.37 (5.0)
0.31 {1.73}(2.4)
0.36 {2.04} (3.3)
3.50 (3.)
4.96 (1.9)
0"08 {1.41}(1.6)
0"28 {5.07}(1.7)
0.05 {.o8}(.7)
0.15 {5’78}(2"0)
1.28 (1.7)
8.41 (1.8)
4.0 {0.92 (10.4)
18.75 {4.35}(11.3)
o.o4 {0.03}(5.)
0.18 {0.14}(4.5)
1.64 (4.1)
2"57 (1.4)
6"82 {0.53} (7.9)
9.91 {0.77}(4.3)
1.05 (2"8)
1.00 (2"3)
1.5 {0"27} (5.1)
6.83 {1.23}(4.1)
8. (o.88)
9.8 (0.95)
10.2 (1.18)
7.4 (0.69)
9.49 (1.14)
3.46 (0.33)
6"2 (0.69)
15.7 (1.42)
11.3 (1.4)
17.9 (1.73)
10.1 (1.18)
9.51 (0.83)
7.5 (0"82)
12"2 (1.15)
1.59 (1.7)
1.92 (1.6)
3.11 (2"5)
4.17 (2"7)
0.08 (2.4)
0.17 (3.1)
U Urine samples.
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Conclusion References
The XL demonstrates analytical equivalence to that of
previous Dimension systems. It is a user-friendly system
with many features for easy operation for a large hospital
laboratory. The instrument is capable of assaying 52
analytes on a random access basis, with a throughput
of 740 tests/hour. The system also has 10 open channel
applications. The majority of the chemistries have a
calibration stability of approximately 90 days, and the
immunoassays have a calibration stability of at least 30
days. The XL design also serves as a suitable platform for
further workstation consolidation, such as addition of
heterogeneous assay formats and robotic sampling.
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